关于多发性骨髓瘤临床决策的患者偏好
Ghulam Rehman Mohyuddin1, Rajshekhar Chakraborty2, Katherine Berger3
1Division of Hematology, Huntsman Cancer Center, University of Utah, Salt Lake City, Salt Lake City, UT.
JCO oncology practice
|July 24, 2025
概括
患有多发性骨髓瘤的患者经常拒绝改善无进展生存率 (PFS) 的治疗,如果它们不能提高整体生存率 (OS) 并引起显著的毒性.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 患者报告的结果
背景情况:
- 多发性骨髓瘤治疗的目的是延长存活时间和改善生活质量.
- 了解患者的优先事项对于治疗选择的共同决策至关重要.
研究的目的:
- 调查患者对多发性骨髓瘤治疗的偏好,其无进展生存期 (PFS) 和整体生存期 (OS) 的好处各不相同.
- 在面对治疗选择时确定患者的优先事项,涉及有效性和毒性之间的权衡.
主要方法:
- 通过HealthTree Cure Hub,对患有多发性骨髓瘤和相关的血细胞失分症的患者进行了一项调查.
- 患者评估了四种不同的治疗方案,具有不同的PFS,OS和毒性概况.
主要成果:
- 56%的患者更喜欢四种药物治疗方案,而不是前线治疗的三种药物治疗方案,尽管类似的操作系统和毒性增加.
- 50%的人选择了改善PFS但不改善OS的整合处理.
- 只有17%的人选择两种药物维持疗法而不是一种药物治疗以改善PFS,7%的人接受了治疗复发性疾病以改善PFS,但没有OS益处和增加毒性.
结论:
- 患者的决策在很大程度上受到治疗对整体存活时间 (OS) 的影响以及实质性的临床,财务或时间毒性的存在的影响.
- 许多患者优先考虑OS和毒性,而不是PFS改善,因为这些并不能转化为更好的长期生存结果.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.2K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
相关概念视频
01:27Nursing Ethical Principles II
1.3K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
1.3K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Ethical Issues
1.2K
Nurses are essential in patient care, upholding the ethical principles of their profession and effectively navigating ethical dilemmas. Neglecting ethical issues can lead to inadequate patient care, compromised therapeutic relationships, and moral distress among healthcare workers.
Ethical Concerns in Healthcare:
Ethical Concerns in Healthcare:
1.2K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:30Ethical Dilemmas II
1.3K
Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:
1.3K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114